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Abstract 
 
Ovarian cancer causes more deaths than any other cancer of the female reproductive tract, 
often progressing undetected into advanced stages, in which treatment becomes difficult. The 
standard of care therapy for ovarian cancer is a cytoreductive surgery followed by a demanding 
schedule that typically involves 3-6 cycles of taxane (paclitaxel or docetaxel) and platinum 
compound (carboplatin or cisplatin) administered intravenously every three weeks.1 
Subcutaneous injection of the in-situ forming implant (ISFI) system loaded with paclitaxel (PX) 
serves as an attractive alternative to the current standard of care treatment due to ease of 
administration, long-acting and controlled release, and potential to enhance antitumor efficacy. 
The ISFI is a syringeable solution based on a water-miscible organic solvent, N-methyl-2-
pyrrolidone, and biodegradable polymer, poly(lactic-co-glycolic acid), that precipitates upon 
injection to form an implant. When loaded with PX, the ISFI system releases the drug at 
controlled rates for weeks to months. The ISFI is a promising platform for PX delivery that 
potentially allows higher drug concentrations at the tumor site and mitigates systemic toxicity. 
Developmental studies for the optimization and characterization of PX-ISFI formulations 
included drug solubility, in vitro release studies, viscosity analysis, and stability studies. 
Solubility of PX in ISFI suspensions was increased by increasing the ratio of polymer. Release 
studies performed using three formulations of varying PLGA/NMP ratios demonstrated 
controlled release patterns with burst release <10% within the first 24 hours. As solvent ratio 
increased, visually determined PX solubility and cumulative PX release with respect to total drug 
loaded increased. Decreased PX-loading resulted in faster release kinetics and increased stability. 
A 4-fold increase in viscosity of ISFI was observed after PX was loaded to 80% of maximum PX 
solubility in 1:4 and 1:8 PLGA/NMP formulations. All formulations investigated were 
syringeable with an 18-gauge needle. 
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Introduction 
 
Ovarian cancer causes more deaths than any other gynecologic cancer of the reproductive 
system, often progressing asymptomatically in the early stages and becoming more difficult to 
treat as it spreads throughout the pelvis and abdomen. The 5-year relative survival for all types of 
ovarian cancer is 46.5%.2 The standard of care treatment involves 3-6 cycles of intravenous (IV) 
chemotherapy, consisting of a platinum compound (cisplatin or carboplatin) and a taxane 
(paclitaxel or docetaxel), administered every three weeks depending on the stage of cancer.1 
Paclitaxel (PX) is a drug that interrupts microtubule function during mitosis and is FDA-
approved to treat several types of cancers, including breast, pancreatic, and non-small cell lung 
cancers.3 Since there is currently no long-acting treatment for ovarian cancer, this study aims to 
introduce the PX-loaded in-situ forming implant (PX-ISFI) as an attractive alternative to the 
current standard of care therapy for ovarian cancer due to its ease of administration and 
sustained, controlled release of PX.  
The ISFI is a drug delivery system that has recently gathered wide research interest for its 
biocompatibility, simple administration, and ability to provide long-acting, controlled release of 
drugs. The ISFI in this study is an example of the ATRIGEL® Delivery System, a syringeable 
solution consisting of a polymer, poly(lactic-co-glycolic acid) (PLGA), that can be co-dissolved 
with drug in a water-miscible solvent, N-methyl-2-pyrrolidone (NMP). Upon injection of the 
drug-loaded ISFI solution, the organic solvent diffuses out, leaving behind the hydrophobic 
polymer and drug to precipitate and form an implant.4 Solvent displacement, diffusion, and 
polymer degradation over weeks to months allow the drug that is entrapped within the implant to 
be released at a controlled rate. Drug release kinetics of ISFIs can be fine-tuned by modifying the 
selection of solvent, polymer composition, polymer molecular weight, polymer/solvent ratio, and 
drug-loading. Studies detailing the mechanisms and kinetics of the transition from ISFI solution 
to solid or semi-solid have been investigated.5,6 
The ATRIGEL Delivery System has been approved by the FDA in ELIGARD®, a 
marketed leuprolide acetate treatment for prostate cancer that is injected subcutaneously and lasts 
1, 3, 4, or 6 months.7 ELIGARD contains the same PLGA (50:50 monomer ratio, MW 40 kDa8) 
used in the ISFI system of this study and thus serves as a model for developing the PX-ISFI 
system.  
PX is a small, hydrophobic molecule (<1 µg/mL solubility in water at 25°C)3 that has 
high solubility in NMP (20 mg PX/mL NMP), a polar aprotic solvent. PX is metabolized by 
hydrolysis of its ester groups and degrades under acidic conditions by cleavage of its oxetane 
ring.9 Controlled release of PX by ISFIs provides sustained drug exposure to the tumor. 
Compared to IV therapy, subcutaneous administration of the drug-loaded ISFI near the tumor 
site delivers higher drug concentrations to the tumor, extends drug exposure, and reduces 
systemic toxicity.10  
PLGA is a biodegradable copolymer that has been increasingly used in biomedical 
applications due to its thermal stability in the absence of water and controlled degradation into 
nontoxic products. PLGA is soluble in NMP and degrades in aqueous environments by 
hydrolysis of ester bonds.11 Although many studies have been conducted on PLGA degradation 
and effects of solvent on PLGA,12,13,14 further studies regarding the interaction between the 
ATRIGEL system and PX are needed.  
The objective of this study was to investigate drug solubility, stability, viscosity, and in 
vitro drug release of PX-ISFIs to optimize formulations for future in vivo testing. Solubility of 
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PX in various polymer/solvent ratios of ISFI was examined to determine maximum drug-
loading. In vitro drug release studies were conducted to examine the effect of PX concentration 
and polymer/solvent ratio on drug release kinetics. PX-ISFIs were subjected to conditions with 
varying temperature and humidity to determine the stability and shelf-life of the formulations. 
Viscosities of ISFI formulations were measured prior to and after loading with PX to investigate 
whether the PX-ISFI solution was syringeable for injection.  
 
 
Materials and Methods 
 
Materials: 
 50:50 Poly(DL-lactide-co-glycolide) (density 1.34 g/mL, IV 0.26-0.54 dL/g, Tg 45-50°C, 
MW 40 kDa8) was purchased from LACTEL (Birmingham, AL, USA). PharmasolveTM N-
methyl-2-pyrrolidone was purchased from Ashland (Wilmington, DE, USA). Paclitaxel was 
purchased from LC Laboratories (Woburn, MA, USA).  
 
Preparation of ISFIs and drug-loading: 
PLGA was dissolved in NMP by sonicating the mixture for 20-30 minutes at 21°C to 
achieve desired ratio of PLGA to NMP in the ISFI (1:30, 1:8, and 1:4). PX was dissolved in the 
placebo ISFI solution by spinning on rotoevaporator with vacuum off in 40°C water bath to 
result in appropriate PX concentration (% w/w).  
 
 
Determination of paclitaxel solubility in ISFI: 
 Placebo ISFI (1:4 and 1:8 PLGA/NMP) was oversaturated (visually translucent) with 
weighed quantity of PX. PX-ISFI mixture was centrifuged at 25°C and 14 rcf for 1 hour (1:8 
PLGA/NMP) or 2 hours (1:4 PLGA/NMP). Supernatant was analyzed by HPLC to quantify PX 
concentration of saturated ISFI, using a WATERS Symmetry C18 5m column at 231 nm.  
 
 
In vitro drug release:   
Release medium (200 mL) consisted of 2% (w/w) solutol in 0.01 M phosphate buffer 
saline solution (pH 7.4). Four depot formulations (Table 1), each consisting of a specific PLGA 
/NMP ratio and loaded with PX (% w/w), were created. The depot of a known mass was quickly 
dispensed into the release media using a pipet. At specific time points, a 1-mL sample of release 
medium was collected and replaced with fresh medium. Release samples were analyzed by 
HPLC to quantify PX concentration using a WATERS Symmetry C18 5m column at 249 nm.  
 
 
Rheology Analysis: ISFI Viscosity Measurement:  
Viscosity of 1:4 PLGA/NMP (36.0% w/w PX) and 1:8 PLGA/NMP (40.0% w/w PX) 
was measured at 25°C prior to and after loading with PX, using Rheometer Model DV-III+, 
Spindle 40 at 0.5 RPM (1:4 PLGA/NMP formulations) and 2.0 RPM (1:8 PLGA/NMP 
formulations). 
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Accelerated Stability:  
1:8 PLGA/NMP (40% and 32% w/w PX), 1:4 PLGA/NMP (36% and 28% w/w PX) 
formulations were stored in three conditions (room temperature and ambient humidity, 25°C and 
60% humidity, or  40°C and 70% humidity) for one month. The percent (w/w) of PX loaded was 
80% theoretical saturation of each formulation and then a further 80% saturation of these 
concentrations based on preliminary solubility studies. Daily visual observations were made, and 
samples from each formulation and condition were analyzed weekly by HPLC with WATERS 
Symmetry C18 5mm column at 231 nm to determine PX concentration (% w/w). HPLC samples 
from unstable, heterogeneous mixtures were taken from the clear phase. Stability was measured 
over time by observing the change in PX concentration relative to the concentration at time 0. 
 
 
Results 
 
Determination of drug solubility in ISFI 
 
Table 1. Solubility of paclitaxel in ISFI solutions (mg/mL and % w/w) 
ISFI Formulation 
(PLGA/NMP) 
Analytical* PX 
Concentration (mg/mL) 
Theoretical† PX 
Concentration (% w/w) 
1:4 0.397 ± 0.03 56.6 ± 1.0 
1:8 0.362 ± 0.04 51.6 ± 5.7 
 
*Analytical – by HPLC 
†Theoretical – by weight 
 
When the method described was used, both analytical and theoretical PX concentrations 
demonstrated that the 1:4 PLGA/NMP formulation dissolved more PX than did the 1:8 
PLGA/NMP formulation. However, the PX-loaded ISFI formulations (Table 1) were suspensions 
rather than homogenous solutions, and therefore differed from the maximum PX-loading 
determined visually (Table 2). 
 
 
In vitro drug release  
 
Four ISFI formulations with varying ratios of PLGA/NMP and PX-loading (Table 2) 
were dropped in 2% solutol and PBS solution, which imitated an in vivo injection site, to 
examine the effect of polymer/solvent ratio and drug loading on release kinetics.  
The effect of polymer/solvent ratio was examined by testing three ratios (1:4, 1:8, and 
1:30) of PLGA/NMP at similar PX-loading (% w/w) near maximum drug solubility. At a 
common endpoint of approximately 99 days for PX-ISFI Formulations 1, 2, and 4 (Table 1), the 
larger the ratio of solvent, the larger the cumulative PX (% w/w) was released (Table 3).  
To test the effect of drug loading, the ISFI ratio of 1:8 PLGA/NMP was kept constant in 
Formulations 2 and 3 while varying the percent of drug loaded (50.5% and 25.0% w/w). A 
comparison of the two 1:8 PLGA/NMP formulations showed that the 25.0% w/w PX formulation 
released a larger cumulative percentage of total drug loaded within the same amount of time than 
did the 50.5% w/w PX formulation (Table 3). As described in similar ISFI drug delivery 
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studies,5,6 decreased drug-loading resulted in faster release kinetics. For this reason, although 
25.0% w/w PX formulation was loaded with nearly half the amount of PX as the 50.5% w/w PX 
formulation, both depots released similar quantities of drug in milligrams in the first 99 days 
(Table 3). Figure 2 displays the similar controlled rates of PX release between these 1:8 
PLGA/NMP formulations, especially within the first 45 days.   
 
 
Table 2. Composition of depot formulations in release study 
Formulation PLGA:NMP % (w/w) PX PLGA:NMP:PX 
1 1:4 46.0 1:4:2.5 
2 1:8 50.5 1:8:4.5 
3 1:8 25.0 1:8:2.3 
4 1:30 59.3 1:30:18.4 
 
 
Within the first 24 hours of the study, all formulations showed burst releases of <10% of 
total drug loaded (Fig. 1) and no initial burst, characterized by a burst release of ≥20% within 
the first 24 hours. This indicated that a controlled amount of PX was released during implant 
formation, when solvent diffuses out of the depot, allowing the polymer and PX to precipitate. 
 
 
 
 
 
Figure 1. Cumulative PX released (%) with respect to the total amount of drug loaded in depot. 
Solid lines represent ISFI loaded at maximum PX saturation, determined visually. 
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Figure 2. Cumulative PX released (mg) with solid lines representing ISFI loaded at maximum 
PX saturation, determined visually. 
 
 
 
 
Table 3. The average weight of depot and PX loaded, duration of release, and cumulative PX 
release (% and absolute) near common endpoint. 
PLGA:NMP:PX 
(% w/w PX) 
Depot Weight and 
PX Weight (mg) 
Duration 
(days) 
Total Cumulative 
PX Release (%) 
Total Cumulative 
PX Release (mg) 
1:4:2.5 (46.0%) 12.3 ± 1.8 
(3.89 ± 0.6) 
99 29 1.12 
1:8:4.5 (50.5%) 16.9 ± 0.9 
(5.66 ± 0.3) 
98 36 2.07 
1:8:2.3 (25.0%) 12.6 ± 0.6 
(2.51 ± 0.1) 
99 70 1.77 
1:30:18.4 (59.3%) 14.4 ± 0.6 
(5.36 ± 0.2) 
102 51 2.74 
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Rheology Analysis: ISFI Viscosity Measurement 
 
Viscosity readings of the 1:8 PLGA/NMP ISFI and PX-ISFI (40.0% w/w PX) were 
measured with rotation speed of 2.0 RPM. However, the 0.5 RPM was used for 1:4 PLGA/NMP 
formulations because the 1:4 PLGA/NMP (36.0% w/w PX) solution was too viscous for the 
rheometer to provide a reading at 2.0 RPM. Both 1:4 and 1:8 PLGA/NMP formulations exhibited 
approximately a 4-fold increase in viscosity after PX was loaded to about 80% of PX saturation, 
determined visually (Table 4). All formulations investigated were syringeable with 18-gauge 
needles at 25°C. 
 
 
Table 4. Viscosity measurements before and after drug-loading at 25°C and 2.0 RPM for 1:8 
PLGA/NMP formulations and 0.5 RPM for 1:4 PLGA/NMP formulations.  
 ISFI Density 
(g/mL) 
ISFI  
Viscosity (cP) 
PX-loaded ISFI 
Viscosity (cP) 
1:4 PLGA:NMP 
(36.0% w/w PX) 
1.0933 81 ± 0.9 
 
352 ± 7.6 
1:8 PLGA:NMP 
(40.0% w/w PX) 
1.0911 18 ± 0.5 95 ± 1.4 
 
 
 
Accelerated Stability  
 
Three storage conditions of varying temperature and humidity were tested on two ISFI 
formulations (1:4 and 1:8 PLGA/NMP) with varied drug-loading (% w/w). Increased 
temperature and humidity provided accelerated exposure of conditions that may degrade 
components in the PX-ISFI system to determine shelf life of the formulations. Room temperature 
and ambient humidity represented indoor storage conditions, the 25°C and 60% humidity 
condition imitated indoor storage in humid environments, and the 40°C and 75% humidity 
condition tested stability of formulations near body temperature.  
All PX-ISFI formulations investigated began as transparent, colorless, and homogenous 
solutions. Clear micelles formed as the solutions became unstable. The micelles grew larger and 
aggregated at the bottom of the clear solution, forming a translucent and viscous globule. This 
distinct phase separation indicated that the PX was precipitating out of solution. As the solvent 
evaporated over time, the formulation appeared as a white and waxy solid.  
The relative percent PX in solution was expected to decrease with time due to PX 
precipitating out of solution or degrading. Although this decreasing trend was generally observed 
over time, certain time points showed increases in relative percent PX (i.e. relative % PX 
significantly greater than 100). The increase in relative percent PX was due to HPLC samples 
taken from heterogeneous, unstable solutions. Some HPLC samples of unstable formulations 
may have contained PX micelles that contributed to higher PX concentration measurements. 
However, HPLC analysis showed a single peak representing PX with 13.8 minute retention time. 
No extraneous peaks were present, indicating that PX was not degrading, but was rather 
precipitating out of solution as observed visually. 
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The estimated shelf life of formulations a, b, c, and d (Fig. 3) were 10 days, 21 days, 16 
days, and 30 or more days. The 80% PX saturated formulas, a and c, were less stable and 
resulted in PX precipitating out of solution faster than the 60% or 64% PX saturated formulas, b 
and d. Considering the results of all three storage conditions, the 1:8 PLGA/NMP formulations 
maintained stability longer than the 1:4 PLGA/NMP formulations. An ongoing study of the 1:8 
PLGA/NMP 40.0% w/w PX in 4°C demonstrated phase separation between days 8 and 13, 
indicating that shelf-life was not extended by decreasing the temperature of storage conditions. 
 
 
 
 
Figure 3.  Stability of 1:4 PLGA/NMP (36% and 28% w/w PX) and 1:8 PLGA/NMP (40% and 
32% w/w PX) formulations under storage conditions with varied temperature and humidity for 
one month.  
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Discussion 
  
The maximum PX saturations of ISFIs (1:4 and 1:8 PLGA/NMP) determined by using 
the method in the experimental section were not consistent with those determined visually. After 
centrifugation, PX-ISFI supernatants were visually translucent suspensions rather than 
homogeneous solutions. Although the 1:8 PLGA/NMP ISFI was expected to dissolve more PX 
than the 1:4 PLGA/NMP ISFI because of the larger ratio of solvent, the 1:4 PLGA/NMP ISFI 
demonstrated greater solubility. It was thus concluded that the higher ratio of polymer allowed a 
larger quantity of PX to be suspended in solution. Additional studies with modified method are 
needed to determine paclitaxel solubility in homogeneous ISFI solutions.  
Although a concern with ISFI systems for drug delivery is large initial burst, 
characterized by ≥ 20% drug release within 24 hours, the in vitro cumulative PX release study 
(Fig. 1) showed burst releases <10% in all formulations (Table 1). These results indicated that 
the PX-ISFI system demonstrates controlled drug release kinetics even during implant formation. 
All four formulations (Table 1) demonstrated controlled release kinetics, and the larger 
the solvent ratio, the faster the PX was released and the larger the cumulative percent of PX was 
released. Both 1:8 and 1:4 PLGA/NMP ISFIs are ideal candidates for PX-ISFI systems because 
they minimize exposure to NMP compared to the 1:30 PLGA/NMP formulation while 
demonstrating comparable release kinetics.  
Similar quantities of PX released in the 1:8 PLGA/NMP formulations (50.5% and 25.0% 
w/w PX) indicated that similar drug doses can be delivered with reduced drug-loading due to 
faster release kinetics. This has profound clinical applications, as using less drug can reduce the 
cost of the final product without compromising the dose that the patient receives. PX-ISFI 
systems are tunable based on polymer/solvent ratio and drug-loading. Further release studies are 
needed to assess the effect of drug loading on release kinetics for the 1:4 PLGA/NMP ISFI. 
Viscosity measurements of both 1:4 and 1:8 PLGA/NMP ISFI solutions increased 
significantly after PX was added. The 4-fold increase in viscosity of the PX-loaded ISFI (80% 
saturation) indicated that the hydrophobic drug was interacting with other components of the 
ISFI, likely the hydrophobic polymer. All formulations were syringeable with an 18-gauge 
needle at room temperature and are thus injectable. For in vivo studies and clinical use, ISFI 
solutions will be loaded at lower PX saturation, to maintain viscosity closer to that of the placebo 
ISFI for ease of injection. 
Increased PX-ISFI stability was observed with decreases in drug-loading because of the 
increased solvent/drug ratio and solvent/polymer ratio. The larger NMP concentration allowed 
PX to remain dissolved in the ISFI solution without precipitating. Humidity was a significant 
factor in destabilizing the PX-ISFI formulations, as shown by the results of the 25°C and 60% 
humidity storage conditions, because both PLGA and PX are degraded by hydrolysis. Ongoing 
studies of 1:8 PLGA/NMP (40% w/w PX) in 4°C demonstrated instability between days 8 and 
13 similar to the 60% humidity and 75% humidity storage conditions. These results indicated 
that decreasing temperature does not extend the shelf-life of the 80% saturated PX-ISFI 
formulation and may contribute to phase separation due to decreased solubility.  
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Conclusion and future studies 
 
Due to its long-acting and controlled release, the PX-ISFI system was investigated as an 
alternative to the standard of care treatment for ovarian cancer. ISFI systems have been shown to 
hold large quantities of PX while maintaining syringeability for injection. In vitro release studies 
of PX-ISFI systems demonstrated controlled release with minimal initial burst release and the 
ability to be fine-tuned by modification of polymer/solvent ratio and drug-loading. PX-loaded 
ISFI systems (1:4 and 1:8 PLGA/NMP) demonstrated stability at room temperature and ambient 
humidity for one week to at least one month. In order to reduce exposure to NMP, the 1:8 and 
1:4 PLGA/NMP formulations will be tested further for optimization in vivo. Future studies 
include cytotoxicity assays, DSC analysis, and antitumor efficacy studies in an ovarian cancer 
xenograft mouse model.  
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